ReviewInfection and drug resistance2025
Natural Source-Derived Compounds with Antifungal Activity Against Medically Relevant Fungi.
Review in Infection and drug resistance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- WHO Critical Priority Fungi: A Comprehensive Review of Antifungal Resistance, Emerging Therapeutic Strategies, and the Potential of Antifungal Peptides.International journal of molecular sciences · 2026Review
- Investigation of chitinase B1 inhibitors targeting the cell wall biosynthetic machinery in Aspergillus fumigatus through integrated molecular dynamics and QM/MM.Folia microbiologica · 2026Article
- Formulation-Driven Innovation in Antifungal Therapy: From Nanotechnology to AI-Assisted Design.International journal of nanomedicine · 2026Review
- From tradition to evidence: medicinal plants used for childhood diseases in the Ehlanzeni District, Mpumalanga Province, South Africa.Frontiers in pediatrics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fungal infections represent a growing global public health problem, particularly in immunocompromised individuals. The availability of effective treatments is limited, and the emergence of strains resistant to conventional antifungal agents further complicates disease management. Therefore, it is essential to explore novel therapeutic alternatives. This review analyzes compounds derived from natural sources with potential antifungal activity and highlights their structural and functional diversities. These include plant primary metabolites, fatty acids, antimicrobial peptides, secondary metabolites, crude extracts, terpenoids, essential oils, flavonoids, and saponins, as well as fungal metabolites and compounds extracted from marine algae. These natural products have demonstrated activity against various fungal species through multiple mechanisms of action, making them promising candidates for the development of new antifungal therapies. Compared with synthetic molecules or novel antifungal drugs under development, natural compounds often display lower toxicity, higher availability, and greater chemical diversity, which can be strategically exploited to overcome resistance. The compilation and analysis of this information underscores the value of natural sources as valuable resources in the search for therapeutic alternatives against human mycoses, particularly in the current context of increasing antifungal resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.